Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ARS Pharmaceuticals (SPRY) EBITDA: 2021-2024

Historic EBITDA for ARS Pharmaceuticals (SPRY) over the last 4 years, with Dec 2024 value amounting to $8.2 million.

  • ARS Pharmaceuticals' EBITDA fell 174.15% to -$51.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$80.4 million, marking a year-over-year decrease of 65.39%. This contributed to the annual value of $8.2 million for FY2024, which is 114.93% up from last year.
  • Per ARS Pharmaceuticals' latest filing, its EBITDA stood at $8.2 million for FY2024, which was up 114.93% from -$54.7 million recorded in FY2023.
  • In the past 5 years, ARS Pharmaceuticals' EBITDA ranged from a high of $8.2 million in FY2024 and a low of -$54.7 million during FY2023.
  • Moreover, its 3-year median value for EBITDA was -$34.3 million (2022), whereas its average is -$26.9 million.
  • Per our database at Business Quant, ARS Pharmaceuticals' EBITDA tumbled by 69.32% in 2022 and then surged by 114.93% in 2024.
  • Yearly analysis of 4 years shows ARS Pharmaceuticals' EBITDA stood at -$20.2 million in 2021, then slumped by 69.32% to -$34.3 million in 2022, then plummeted by 59.66% to -$54.7 million in 2023, then skyrocketed by 114.93% to $8.2 million in 2024.